Semaglutide for Alcohol Use Disorder

What Was Tested

This registered phase 2 trial tested Semaglutide.

It had two arms (groups): Semaglutide (experimental) and Sham/Placebo (sham comparator).

Participants will receive sham subcutaneous injections over 9 weeks.

The registry classes the interventions as drug.

More on the Plan

Participants will attend weekly visits for medication or placebo administration.

Who Took Part

Enrollment: 48 actual participants took part.

It was open to people of any sex aged from 21 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Willingness/availability to take study medication and complete study procedures, including attending weekly visits for medication administration, side effect assessments, and glucose monitoring. Ability to communicate and read in English.

The full record lists 5 inclusion and 29 exclusion criteria; among the exclusions: past 30-day use of: sincalide, sulfonylureas, insulin and insulin products or other medications that may interact with semaglutide;, or weight control medications; prior use of semaglutide or other glp-1 agonists; known or suspected hypersensitivity to study medication or related products.

How the Study Was Run

Design: randomized, parallel-group and triple-blind.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Those kept unaware of assignments: participant, investigator and outcomes assessor.

It started in 2022-09-02 with completion listed for 2024-04-12.

It ran at 1 site in United States.

Its stated primary purpose is basic science.

What Was Measured

It also tracked 6 secondary outcomes, for example Change in Cigarette Demand (Cigarette Purchase Task) and Change in Daily Cigarette Use.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide in 48 people.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Semaglutide compound page, all human trials.